Moleculera Labs Story: Lessons in a Capital Efficient Start-Up

Authors

  • Craig Shimasaki

DOI:

https://doi.org/10.5912/jcb858

Abstract

This case study focuses on Moleculera Labs, an emerging biotechnology R&D company developing clinical diagnostics and identifying new therapeutic targets. This article covers commercialization and innovation strategy applicable to an emerging biotech company that has utilized patient-centric, capital efficient, and lean principles for development, validation, and go-to-market execution. This case study includes key factors that are essential for successful biotechnology companies. These range from management of technology, market, and team/leadership risks to dealing with financing, regulatory, IP, and reimbursement issues.

Published

2018-06-12

Issue

Section

Special Section